New guidance encourages pharmaceutical companies to focus research where need is most urgent, amid a rising AMR threat ...

Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx is launching a ground-breaking clinical trial ...

Crestone, Inc. ("Crestone") today announced recent publication in the leading infectious disease journal, The Lancet Infectious Diseases, of positive results from a Phase 2 clinical trial evaluating ...

Acurx Pharmaceuticals, Inc.  ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced ...

Vancomycin has been used with increased frequency during the past 15 years and the most common toxicity with this drug is the "red man syndrome". Other adverse effects include neutropenia, fever, ...

Canada: Researchers have found in a new randomized clinical trial that a 4-week vancomycin pulse and taper regimen showed a ...

About one year ago, I had Clostridioides difficile (C. diff) that was treated with 125 mg of vancomycin for about four weeks. I had none of the usual ...

Spinal infections after spinal surgeries are important complications that increase morbidity and even mortality, besides their economic and social impact 1 – 3. Infections may lead to osteomyelitis, ...

BODIPY-Vancomycin（BODIPY标记万古霉素）是一种将荧光染料BODIPY（硼二吡咯亚甲基）共价偶联至万古霉素分子的化学探针。该复合物保留了万古霉素原有的分子识别特性，同时引入了BODIPY优异的光学性能，使其在生物成像与分子识别研究中具有独特优势。 从分子架构 ...

FITC-Vancomycin 是一种由 万古霉素（Vancomycin） 与 异硫氰酸荧光素（Fluorescein Isothiocyanate，FITC） 通过化学偶联形成的 荧光标记抗生素衍生物。万古霉素是一种糖肽类抗生素，能够特异性结合革兰阳性菌细胞壁中的 D-Ala-D-Ala 肽链末端，从而抑制细菌肽聚糖的合成 ...

Please provide your email address to receive an email when new articles are posted on . However, this finding did not reach statistical significance, the researchers noted. “This is the first ...